APOTEX DONATES HYDROXYCHLOROQUINE FOR A CLINICAL STUDY TO PREVENT INFECTION FROM COVID-19 WITH FRONT LINE HEALTH CARE WORKERS
Mar 23, 2020Toronto, Ontario, March 20th – 2020 – Apotex, Canada’s largest pharmaceutical company, announced today that it is donating Hydroxychloroquine to accelerate a study examining if it prevents infection of COVID-19 in front-line healthcare employees.
The study, conducted by the University Health Network and Unity Health (St Michael's Hospital) in Toronto, aims to gather data from randomized controlled trials which is essential for informing the best practices in protecting our health care workers at this critical time. It is a PreExposure Prophylaxis randomized placebo controlled trial for front line health care workers including emergency room staff and ICU staff.
“We are committed to take whatever actions we can to support our healthcare community as they investigate possible treatments for COVID-19,” said Jeff Watson, President and CEO, Apotex. “Due to anticipated increased demand for this product, we have doubled our planned production outputs, and are in dialogue with governments about additional measures they may wish to take on this specific product.”
Global interest in Hydroxychloroquine has surged with some governments already adding the product to their COVID-19 treatment protocols. Other countries are also considering the impact of this product, including the United States who requested that it be made available for use immediately.
Apotex is working around the clock to protect the health and safety of its employees in order to minimize disruption to Canada’s drug supply. “Canada is fortunate to have domestic manufacturing of cost effective pharmaceuticals within its borders,” said Jeff Watson. “The importance of this local capability, especially during times of a pandemic cannot be overstated.”
In addition to producing almost 100% of its portfolio for Canadians in Canada, Apotex is also the largest manufacturer of active pharmaceutical ingredients in the country.
About Apotex Inc.
Apotex Inc. is a proudly Canadian, global pharmaceutical company that produces high-quality, affordable medicines for patients around the world. Apotex employs almost 8,000 people worldwide in manufacturing, R&D, and commercial operations. Apotex Inc. exports to more than 100 countries and territories and operates in more than 45 countries, with a significant presence in Canada, the US, Mexico, and India. Through vertical integration, Apotex is comprised of multiple divisions and affiliates including Apotex Inc., focused on generics; Apobiologix, a division of Apotex Inc. focused on biosimilar development; Aveva, an affiliate of Apotex Inc. fully integrated global developer and manufacturer of complete transdermal solutions; Apotex Consumer Products, a division of Apotex Inc. focused on brand name products; and Global Active Pharmaceutical Ingredients (GAPI), a division of Apotex Inc. focused on the manufacturing of active pharmaceutical ingredients (API) for Apotex and third parties. For more information visit: www.apotex.com.
-30-
All media enquiries:
Jordan Berman
Vice-President, Global Corporate Communications
PH: 416-401-7487
Mobile: 647-272-2287
Media inquries
Have a question for our media team? Fill out our inquiries form, and we’ll get back to you as soon as possible.
Latest news
-
Sep 18, 2026
Apotex Health Corp. announces closing of upsized bought deal secondary offering
Toronto, Ontario, September 18, 2026 – Apotex Health Corp. ("Apotex" or the "Company") announced today the closing of the previously announced upsized secondary offering (the "Offering") of common shares of the Company (the "Common Shares") by an affiliate of SK Capital Partners ("SK Capital"), API Investment LP ("Sherfam") and Allan Oberman ("Oberman", and together with SK Capital and Sherfam, the "Selling Shareholders").
-
Sep 15, 2026
Apotex Health Corp. announces upsize of bought deal secondary offering to $850 million
Toronto, Ontario, September 15, 2026 - Apotex Health Corp. ("Apotex" or the "Company") announced today that, as a result of strong demand, Apotex, an affiliate of SK Capital Partners ("SK Capital"), API Investment LP ("Sherfam") and Allan Oberman ("Oberman", and together with SK Capital and Sherfam, the "Selling Shareholders") have entered into an amended agreement with the syndicate of underwriters (the "Underwriters") led by RBC Capital Markets, TD Securities Inc., and Scotiabank, as joint lead bookrunners, and BMO Capital Markets and Jefferies Securities, Inc., as joint bookrunners, to increase the size of the previously announced bought deal secondary offering of common shares of the Company (the "Common Shares"). Under the amended agreement, the Underwriters have agreed to purchase 25,000,000 Common Shares from the Selling Shareholders at a purchase price of $34.00 per Common Share for total gross proceeds of approximately $850,000,000 (the "Upsized Offering").
-
Sep 15, 2026
Apotex Health Corp. announces $750 million bought deal secondary offering
Toronto, Ontario, September 14, 2026 - Apotex Health Corp. ("Apotex" or the "Company") announced today that Apotex, an affiliate of SK Capital Partners ("SK Capital"), API Investment LP ("Sherfam") and Allan Oberman ("Oberman", and together with SK Capital and Sherfam, the "Selling Shareholders") have entered into an agreement with a syndicate of underwriters (the "Underwriters") led by RBC Capital Markets, TD Securities Inc., and Scotiabank, as joint lead bookrunners, and BMO Capital Markets and Jefferies Securities, Inc., as joint bookrunners, to complete a secondary offering on a bought deal basis (the "Offering") of common shares of the Company (the "Common Shares"). Under the agreement, the Underwriters have agreed to purchase 22,058,825 Common Shares from the Selling Shareholders at a purchase price of $34.00 per Common Share for total gross proceeds of approximately $750,000,050.